Literature DB >> 1437204

Bilateral thyroarytenoid denervation: a new treatment for laryngeal hyperadduction disorders studied in the canine.

J A Sercarz1, G S Berke, Y Ming, J Rothschiller, M C Graves.   

Abstract

Adductor spasmodic dysphonia is a vocal disorder of uncertain etiology with no satisfactory long-term treatment. Recently, injection of botulinum toxin (Botax) into the thyroarytenoid (TA) muscle has been used as an effective temporary treatment. A surgical counterpart to bilateral TA Botox injection is described in this article. Bilateral thyroarytenoid denervation was performed through a window in the thyroid cartilage in seven canines, including four that were studied 3 months after the procedure. No serious complications occurred in the animals, each maintaining full vocal fold abduction and adduction. In all cases, anticipated physiologic changes in laryngeal function were observed, including the inability to generate high subglottic pressures during high levels of laryngeal nerve (RLN) stimulation. In two of the surviving animals, the ansa cervicalis was used to reinnervate the TA muscle, thereby preventing the possibility of reinnervation from the proximal RLN stump while limiting TA atrophy and fibrosis. Bilateral TA denervation represents a hopeful new long-term approach to spasmodic dysphonia treatment.

Entities:  

Mesh:

Year:  1992        PMID: 1437204     DOI: 10.1177/019459989210700508

Source DB:  PubMed          Journal:  Otolaryngol Head Neck Surg        ISSN: 0194-5998            Impact factor:   3.497


  2 in total

1.  Vocal outcome after endoscopic thyroarytenoid myoneurectomy in patients with adductor spasmodic dysphonia.

Authors:  Sachin Gandhi; Marc Remacle; Prasun Mishra; Vrushali Desai
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-06-12       Impact factor: 2.503

2.  Bipolar radiofrequency-induced thermotherapy (rfitt) for the treatment of spasmodic dysphonia. A report of three cases.

Authors:  Marc Remacle; Isabelle Plouin-Gaudon; Georges Lawson; Jean Abitbol
Journal:  Eur Arch Otorhinolaryngol       Date:  2005-02-26       Impact factor: 2.503

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.